
Genomma Lab Reports Mixed Q2 2026 Results Amid Market Recovery
Genomma Lab Internacional reported a 3.6% decline in like-for-like sales for the second quarter of 2026, as the company navigated a soft retail environment in Mexico and the US. Despite the top-line contraction, the pharmaceutical group managed a 5.5% increase in net income, bolstered by improved margins and reduced financial expenses.





















